{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:28:11Z","timestamp":1768454891822,"version":"3.49.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In our hospital, patients are treated with continuous vancomycin infusion following standard dosing guidelines. Recent literature suggests that obese and neutropenic patients may require increased vancomycin dosages. This study aimed to reassess our dosing guidelines by evaluating how the time and dose required to achieve vancomycin target concentrations differ across specific patient groups compared to all vancomycin patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using hospital records from patients treated with continuous vancomycin infusion between 1 January and 31 December 2023. Adult patients treated according to the antibiotic guidelines, with at least one vancomycin target concentration measurement, were included. We compared the time and maintenance dose required to reach target concentrations in neutropenic patients (neutrophils &amp;lt;1.5\u200a\u00d7\u200a109\/L), patients weighing &amp;gt;100\u2005kg, patients with augmented renal clearance (ARC; glomerular filtration rate &amp;gt;130\u2005mL\/min\/1.73\u2005m2) and all vancomycin patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median time to reach target was 2.59\u2005days for all vancomycin patients (n\u200a=\u200a244), and 2.73, 2.74, and 3.39\u2005days for ARC patients (n\u200a=\u200a5), neutropenic patients (n\u200a=\u200a15) and patients weighing &amp;gt;100\u2005kg (n\u200a=\u200a50), respectively. The median maintenance dose was 2000\u2005mg\/day among all vancomycin patients, compared to 3000\u2005mg\/day for patients weighing &amp;gt;100\u2005kg and neutropenic patients and 4000\u2005mg\/day for ARC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>According to current guidelines, there is no significant difference in the time required to achieve vancomycin target concentrations between neutropenic patients, ARC patients and all vancomycin patients. However, patients weighing &amp;gt;100\u2005kg took nearly a day longer to reach target concentrations (P\u200a&amp;lt;\u200a0.001) and required higher maintenance doses, as did neutropenic and ARC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf424","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:35:13Z","timestamp":1764171313000},"source":"Crossref","is-referenced-by-count":0,"title":["Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients"],"prefix":"10.1093","volume":"81","author":[{"given":"W","family":"T\u00f6pfer","sequence":"first","affiliation":[{"name":"Unit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K H M","family":"Larmen\u00e9-Beld","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Isala Hospital , Dr. van Heesweg 2, Zwolle 8025AB ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J","family":"Veen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Isala Hospital , Dr. van Heesweg 2, Zwolle 8025AB ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J D","family":"Machiels","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Isala Hospital , Zwolle ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E J","family":"Smolders","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Isala Hospital , Dr. van Heesweg 2, Zwolle 8025AB ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2026011413272165300_dkaf424-B1","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0025-6196(12)65799-1","article-title":"Vancomycin","volume":"66","author":"Wilhelm","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"2026011413272165300_dkaf424-B2","author":"TDM Monograph Vancomycin"},{"key":"2026011413272165300_dkaf424-B3","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","article-title":"Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study","volume":"45","author":"Wysocki","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413272165300_dkaf424-B4","first-page":"A2667","article-title":"Continuous and intermittent infusion of vancomycin equally effective: review of the literature","volume":"155","author":"van Maarseveen","year":"2011","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2026011413272165300_dkaf424-B5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bcp.14144","article-title":"Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals","volume":"86","author":"Smit","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026011413272165300_dkaf424-B6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: a systematic review","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2026011413272165300_dkaf424-B7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1186\/s12879-021-06840-y","article-title":"The impact of early target attainment of vancomycin in critically ill patients with confirmed Gram-positive infection: a retrospective cohort study","volume":"21","author":"Al Sulaiman","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026011413272165300_dkaf424-B8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40262-023-01324-5","article-title":"How to dose vancomycin in overweight and obese patients with varying renal (dys)function in the novel era of AUC 400\u2013600 mg\u00b7h\/L-targeted dosing","volume":"63","author":"Zhang","year":"2024","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf424\/65551280\/dkaf424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf424\/65551280\/dkaf424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:27:28Z","timestamp":1768415248000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf424\/8343464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf424","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,26]]},"article-number":"dkaf424"}}